Targeted noninvasive control of the nervous system and end-organs may enable safer and more effective treatment of multiple diseases compared to invasive devices or systemic medications. One target is the cholinergic anti-inflammatory pathway that consists of the vagus nerve to spleen circuit, which has been stimulated with implantable devices to improve autoimmune conditions such as rheumatoid arthritis. Here we report that daily noninvasive ultrasound (US) stimulation targeting the spleen significantly reduces disease severity in a mouse model of inflammatory arthritis. Improvements are observed only with specific parameters, in which US can provide both protective and therapeutic effects. Single cell RNA sequencing of splenocytes and experiments in genetically-immunodeficient mice reveal the importance of both T and B cell populations in the anti-inflammatory pathway. These findings demonstrate the potential for US stimulation of the spleen to treat inflammatory diseases.
Bibliographical noteFunding Information:
Due to the unique potential of US to provide a noninvasive, non-pharmacological approach to treating inflammatory diseases, as well as the consistency in results across studies between two independent research groups, we have initiated a pilot clinical trial (Clin-icalTrials.gov Identifier: NCT03690466) funded by the United States Defense Advanced Research Projects Agency (DARPA) to explore the use of US as an alternative therapy for human patients with rheumatoid arthritis. Positive findings from this clinical trial, combined with the encouraging data presented in these companion papers, will open new opportunities for applying US of peripheral nerves and end-organs to treat a range of chronic inflammatory diseases, such as rheumatoid arthritis and other health conditions.
We thank Cory Gloeckner, Tianqi Li, John Basile, Gerardo Rodriguez, Mark Hamilton, and Alyona Haritonova for their assistance with the project. We also thank Erik Peterson, whose guidance on the project’s clinical relevance was much appreciated. This work was supported by the United States Defense Advanced Research Projects Agency (DARPA) Electrical Prescriptions (ElectRx) Program (DARPA BTO HR0011-16C-0014) under the auspices of Doug Weber and Eric Van Gieson, with additional support from Gretchen Knaack, Tyler Best, and Rebekah Cecil at DARPA. The views, opinions and/or findings expressed are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government.
© 2019, The Author(s).
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.